<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Apimeds Pharmaceuticals Us, Inc. — News on 6ix</title>
<link>https://6ix.com/company/apimeds-pharmaceuticals-us-inc</link>
<description>Latest news and press releases for Apimeds Pharmaceuticals Us, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 24 Mar 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/apimeds-pharmaceuticals-us-inc" rel="self" type="application/rss+xml" />
<item>
<title>Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery</title>
<link>https://6ix.com/company/apimeds-pharmaceuticals-us-inc/news/apimeds-pharmaceuticals-us-inc-announces-material-breach-of-merger-agreement-by-inscobee-inc-ks006490-and-apimeds-inc-prepares-filing-emergency-action-in-delaware-court-of-chancery</link>
<guid isPermaLink="true">https://6ix.com/company/apimeds-pharmaceuticals-us-inc/news/apimeds-pharmaceuticals-us-inc-announces-material-breach-of-merger-agreement-by-inscobee-inc-ks006490-and-apimeds-inc-prepares-filing-emergency-action-in-delaware-court-of-chancery</guid>
<pubDate>Tue, 24 Mar 2026 12:30:00 GMT</pubDate>
<description>MATAWAN, N.J. & SEOUL, South Korea, March 24, 2026--MindWave Innovations Inc., a Delaware corporation and wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. ("APUS" or the "Company") (NYSE American: APUS), today announced that on March 20, 2026, Inscobee Inc. (KS:006490) and its wholly owned subsidiary Apimeds Inc. (together, "Inscobee"), in concert with certain other stockholders, filed an Amendment No. 2 to Schedule 13D with the Securities and Exchange Commission purporting to effect</description>
</item>
<item>
<title>Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)</title>
<link>https://6ix.com/company/apimeds-pharmaceuticals-us-inc/news/apimeds-pharmaceuticals-and-lokahi-therapeutics-announce-fda-type-c-meeting-scheduled-for-lt100-apitox</link>
<guid isPermaLink="true">https://6ix.com/company/apimeds-pharmaceuticals-us-inc/news/apimeds-pharmaceuticals-and-lokahi-therapeutics-announce-fda-type-c-meeting-scheduled-for-lt100-apitox</guid>
<pubDate>Wed, 11 Feb 2026 21:51:00 GMT</pubDate>
<description>MATAWAN, N.J. & LA JOLLA, Calif., February 11, 2026--Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP) has confirmed a Type C meeting to discuss LT-100 (Apitox), a non-opioid biologic candidate being developed for the treatment of the signs and symptoms of osteoarthritis (OA). The meeting will be conducted via teleconference on Monday, May 4, 2026.</description>
</item>
<item>
<title>Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation</title>
<link>https://6ix.com/company/apimeds-pharmaceuticals-us-inc/news/apimeds-brings-ai-futures-labtm-to-the-palouse-partnering-with-the-university-of-idaho-to-shape-the-future-of-biotech-innovation</link>
<guid isPermaLink="true">https://6ix.com/company/apimeds-pharmaceuticals-us-inc/news/apimeds-brings-ai-futures-labtm-to-the-palouse-partnering-with-the-university-of-idaho-to-shape-the-future-of-biotech-innovation</guid>
<pubDate>Mon, 10 Nov 2025 15:00:00 GMT</pubDate>
<description>MATAWAN, N.J. & MOSCOW, Idaho, November 10, 2025--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("Apimeds") today announced the expansion of its ai² Futures Lab™ program through a new collaboration with the University of Idaho College of Business and Economics, beginning in the Spring 2026 semester. The initiative connects student teams with real-world biopharma business development projects, reinforcing Apimeds’ commitment to fostering innovation, leadership, and discovery across the h</description>
</item>
<item>
<title>Apimeds Pharmaceuticals says "I love my Ducks" with new ai² Futures Lab™ Program collaboration with the University of Oregon’s Lundquist College of Business</title>
<link>https://6ix.com/company/apimeds-pharmaceuticals-us-inc/news/apimeds-pharmaceuticals-says-i-love-my-ducks-with-new-ai-futures-labtm-program-collaboration-with-the-university-of-oregons-lundquist-college-of-business</link>
<guid isPermaLink="true">https://6ix.com/company/apimeds-pharmaceuticals-us-inc/news/apimeds-pharmaceuticals-says-i-love-my-ducks-with-new-ai-futures-labtm-program-collaboration-with-the-university-of-oregons-lundquist-college-of-business</guid>
<pubDate>Tue, 14 Oct 2025 07:02:00 GMT</pubDate>
<description>MATAWAN, N.J. & EUGENE, Ore., October 14, 2025--Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) ("Apimeds") today announced the expansion of the Apimeds ai² Futures Lab program through a new collaboration with the University of Oregon’s Lundquist College of Business, starting with the Winter 2026 quarter. The initiative connects student teams with real-world biopharma business development projects, reinforcing Apimeds’ commitment to fostering innovation, leadership, and discovery across the health</description>
</item>
<item>
<title>Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development</title>
<link>https://6ix.com/company/apimeds-pharmaceuticals-us-inc/news/apimeds-expands-ai-future-labs-program-to-include-university-of-san-diego-students-in-biotech-business-development</link>
<guid isPermaLink="true">https://6ix.com/company/apimeds-pharmaceuticals-us-inc/news/apimeds-expands-ai-future-labs-program-to-include-university-of-san-diego-students-in-biotech-business-development</guid>
<pubDate>Mon, 15 Sep 2025 22:24:00 GMT</pubDate>
<description>MATAWAN, N.J., September 15, 2025--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("Apimeds") today announced the expansion of its ai² Future Labs program by engaging graduate students from the University of San Diego’s Knauss School of Business. The initiative is designed to identify promising pharmaceutical assets critical to improving human health while cultivating the next generation of business leaders for the biopharmaceutical industry.</description>
</item>
<item>
<title>Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program</title>
<link>https://6ix.com/company/apimeds-pharmaceuticals-us-inc/news/apimeds-welcomes-fda-draft-guidance-as-catalyst-for-advancing-apitox-non-opioid-pain-program</link>
<guid isPermaLink="true">https://6ix.com/company/apimeds-pharmaceuticals-us-inc/news/apimeds-welcomes-fda-draft-guidance-as-catalyst-for-advancing-apitox-non-opioid-pain-program</guid>
<pubDate>Fri, 12 Sep 2025 01:54:00 GMT</pubDate>
<description>MATAWAN, N.J., September 12, 2025--Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) today welcomed the U.S. Food and Drug Administration’s (FDA) newly released draft guidance on the development of non-opioid pain therapies, highlighting its potential to accelerate the company’s lead program, Apitox, for chronic osteoarthritis pain. The draft guidance, entitled "Development of Non-Opioid Analgesics for Chronic Pain, Draft Guidance for Industry", can be found here: https://www.fda.gov/regulatory-info</description>
</item>
<item>
<title>Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future Labs</title>
<link>https://6ix.com/company/apimeds-pharmaceuticals-us-inc/news/apimeds-pharmaceuticals-us-inc-partners-with-university-of-alabama-to-advance-biotech-business-development-via-ai-future-labs</link>
<guid isPermaLink="true">https://6ix.com/company/apimeds-pharmaceuticals-us-inc/news/apimeds-pharmaceuticals-us-inc-partners-with-university-of-alabama-to-advance-biotech-business-development-via-ai-future-labs</guid>
<pubDate>Mon, 25 Aug 2025 18:11:00 GMT</pubDate>
<description>MATAWAN, N.J., August 25, 2025--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("Apimeds") today announced the launch of its ai² Future Labs program in partnership with The University of Alabama Culverhouse College of Business’s STEM Path to the MBA program. The initiative aims to identify important assets critical to improving human health and to cultivate the next generation of pharmaceutical industry business leaders.</description>
</item>
<item>
<title>Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division</title>
<link>https://6ix.com/company/apimeds-pharmaceuticals-us-inc/news/apimeds-expands-leadership-team-with-dr-susan-kramer-to-lead-product-development-and-brian-peters-to-lead-its-ai-division</link>
<guid isPermaLink="true">https://6ix.com/company/apimeds-pharmaceuticals-us-inc/news/apimeds-expands-leadership-team-with-dr-susan-kramer-to-lead-product-development-and-brian-peters-to-lead-its-ai-division</guid>
<pubDate>Tue, 15 Jul 2025 21:34:00 GMT</pubDate>
<description>MATAWAN, N.J., July 15, 2025--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("Apimeds" or the "Company"), a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered, bee venom-based therapeutic, today announced two key additions to its executive leadership team. Susan Kramer, DrPH, has been appointed Senior Vice President of Development, and Brian Peters has joined as Head of the Company’s proprietary ai²™ division.</description>
</item>
<item>
<title>Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering</title>
<link>https://6ix.com/company/apimeds-pharmaceuticals-us-inc/news/apimeds-pharmaceuticals-us-inc-announces-closing-of-initial-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/apimeds-pharmaceuticals-us-inc/news/apimeds-pharmaceuticals-us-inc-announces-closing-of-initial-public-offering</guid>
<pubDate>Mon, 12 May 2025 21:14:00 GMT</pubDate>
<description>Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects, today announced the closing of its initial public offering (the “Offering”) of 3,375,000 shares of common stock at a public offering price of $4.00 per share. The s</description>
</item>
<item>
<title>Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering</title>
<link>https://6ix.com/company/apimeds-pharmaceuticals-us-inc/news/apimeds-pharmaceuticals-us-inc-announces-pricing-of-initial-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/apimeds-pharmaceuticals-us-inc/news/apimeds-pharmaceuticals-us-inc-announces-pricing-of-initial-public-offering</guid>
<pubDate>Thu, 08 May 2025 21:00:00 GMT</pubDate>
<description>Hopewell, New Jersey, May 08, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects, today announced the pricing of its initial public offering of 3,375,000 shares of common stock at a price of $4.00 per share. The gross proceeds to Apimeds from the</description>
</item>
</channel>
</rss>